Identification of polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma

Cancer Research

Volumn 69, Issue 5, 2009, Pages 1916-1923

  Nappi, Tito Claudio ^a   Salerno, Paolo ^a   Zitzelsberger, Horst ^c   Carlomagno, Francesca ^a   Salvátore, Giuliana ^b   Santoro, Massimo ^a,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d Dipartimento di Biologia e Patologia Cellulare e Molecolare   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5 METHYL 6 OXO 5,6,7,8 TETRAHYDRO PTERIDIN 2 YLAMINO) 3 METHOXY N (1 METHYL PIPERIDIN 4 YL)BENZAMIDE; BI 2536; CYTOTOXIC AGENT; HISTONE H3; POLO LIKE KINASE 1; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; CYCLIN B; CYCLIN B1; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA CONTENT; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMETAPHASE; PROTEIN ANALYSIS; THYROID CARCINOMA; THYROID FOLLICLE CELL; ANIMAL; CARCINOMA; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY; PHYSIOLOGY; THYROID TUMOR; TUMOR CELL LINE;

ANIMALS; CARCINOMA; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; FEMALE; HUMANS; MICE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 62449333305     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1693     Document Type: Article

References (38)

1. Are C, Shaha AR. Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-464
2. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol 2003;15:78-83.
3. Ordonez N, Baloch Z, Matias-Guiu. X, et al. Undiffer-entiated (anaplastic) carcinoma. In DeLellis RA, Lloyd. RV Heitz PU, Eng C, editors. Tumours of endocrine organs, World Health Organization classification of tumors. Lyon (France): IARC Press; 2004 p. 77-80.
4. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koefiler HP. High prevalence of mutations of the p53 gene in. poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179-184
5. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6: 292-306.
6. Groussin L, Fagin JA. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nat Clin Pract Endocrinol Metab 2006;2:180-181
7. Nikiforov YE. Genetic alterations involved in the transition, from, well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 2004 15:319-327
8. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implica-tions. Endocr Rev 2007;28:742-62.
9. Garcia-Rostan G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005:15:10.199-207.
10. Wu G, Mambo E, Guo Z, et al. Uncommon mutation, but common amplifications, of the PI.K3CA gene in thyroid tumors. J Clin Endocrinol Metab 2005; 90:4688-4693
11. Pierantoni GM, Rlnaldo C, Mottolese M, et al. High-mobility group Al inhibits p53 by cytoplasmic «¡ocalization of its proapoptotic activator HI.PK2. J Clin Invest 2007;117:693-702.
12. Malaguamera R, Vella V, Vigneri R, Frasca F. p53 family proteins in thyroid cancer. Endocr Relat Cancer 2007;14:43-60.
13. Salvátore G, Nappl TC, Salerno P, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007:67:10148-58.
14. Barr FA, Silljé HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev MoI Cell Biol 2004; 5:429-40.
15. Strebhardt K. Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-30
16. Plyte S, Musacchio A. PLKl. inhibitors: setting the mitotic death trap. Curr Biol 2007;17:R280-3.
17. Lenart P, Petronczkl M, Steegmaier M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of Polo-like kinase 1. Curr Biol 2007;17: 304-15.
18. Smith MR, Wilson ML, Hamanaka R, et al. Malignant transformation of mammalian cells initiated by consti-tutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997;234:397-405.
19. Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLKl) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002:94: 1863-77.
20. Liu X, Erikson RL. Polo-like kinase (PIk) 1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sei USA 2003;100:5789-94.
21. Liu X Lei M, Erikson RL. Normal cells, hut not cancer cells, survive severe Plkl depletion. MoI Cell Biol 2006; 26:2093-108.
22. Steegmaier M, Hoffmann M, Baum A, et al. BI 2536, a potent and selective inhibitor of Polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-22.
23. Gumireddy K, Reddy MV Cosenza SC, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plkl, is a potent anticancer agent. Cancer Cell 2005;7:275-86.
24. Mclnnes C, Mazumdar A, Mezna M, et al. Inhibitors of Polo-like kinase reveal roles in spindle-pole mainte-nance. Nat Chem Biol 2006;2:608-17.
25. Peters U, Cherian J, Kim JH, Kwok BH, Kapoor TM. Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem. Biol 2006;2:618-26.
26. Lansing TJ, McConnell RT, Duckett DR, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. MoI Cancer Ther 2007;6:450-59.
27. Uckun FM, Dibirdik I, Qazi S, et al. Anti-breast can tivity of LFM-Al 3, a potent inhibitor of Polo-like kinase (PLK). Bloorg Med Chem 2007;15:800-14.
28. Munzert G, Steinbild S, Frost A, et al. A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 In patients with advanced solid tumors. Proc Am Soc Clin Oncol Annu Meet 2006; 24:3069.
29. Gioannl J, Zanghellinl E, Mazeau. C, et al. Character-ization of a human cell line from an anaplastic carcinoma of the thyroid gland. Bull Cancer 1991;78:1053-62
30. Lee JJ, Foukakis T, Hashemi J, et al. Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. Thyroid 2007;17:289-301.
31. Ogisawa K, Onoda N, Ishikawa T, et al. Establishment and characterization of OCUT-I, an undifferentiated thyroid cancer cell line expressing high level of telomerase. J Surg Oncol 2002;80:197-203.
32. Leboeuf R, Baumgartner JE, Benezra M, et al. BRA.FV600E mutation, is associated with preferential sensitivity to MEK inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 2008;93:2194-201.
33. Chung SH, Onoda N, Ishikawa T, et al. Peroxisome proliferator-activated receptor 7 activation induces cell cycle arrest via the p53-independent pathway in. human anaplastic thyroid cancer cells. Jpn J Cancer Res 2002:93: 1358-65.
34. Tsvetkov LM, Tsekova RT, Xu X, Stern. DF. The Plkl. Polo box domain, mediates a cell cycle and DNA damage regulated Interaction with Chk2. Cell Cycle 2005;4:609-17.
35. Tada S. Cdtl and geminin: role during cell cycle progression and DNA damage in higher eukaryotes. Front Blosci 2007;12:1629-41.
36. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: Mitotic catastrophe. Cell Death Differ 2008:15:1153-62.
37. Fujiwara T, Bandi M, Nitta M, Ivanova EV Branson RT, Pellman. D. Cytokinesis failure generating tetraplolds promotes tumorigenesis in p53-null cells. Nature 2005; 437:1043-7.
38. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005; 65:2698-704.